Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report

  Healthcare Companies Report Conference Presentation Schedule, Stock Price
Updates, and Clinical Study Results - Research Report on Medivation, Envision
               Healthcare, Fonar, Idera Pharma, and Neurocrine

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, January 9, 2014

NEW YORK, January 9, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
Medivation, Inc. (NASDAQ: MDVN), Envision Healthcare Holdings, Inc. (NYSE:
EVHC), Fonar Corp. (NASDAQ: FONR), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA),
and Neurocrine Biosciences Inc. (NASDAQ: NBIX). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Medivation, Inc. Research Report

On January 6, 2014, Medivation, Inc. (Medivation) announced that it will
participate at the upcoming Annual J.P. Morgan Healthcare Conference on
January 13, 2014. According to the Company, David Hung, M.D., President and
CEO of Medivation, is scheduled to make the presentation on the aforesaid date
at 4:30 p.m. PT at the Westin St. Francis Hotel in San Francisco, California.
According to the Company, a live audio webcast of the presentation will be
made available to interested individuals through Medivation's website.
Additionally, Medivation stated that a replay of the webcast will also be made
available on the Company's website for 30 days following the live event. The
Full Research Report on Medivation, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: 

http://www.analystscorner.com/r/full_research_report/4277_MDVN

Envision Healthcare Holdings, Inc. Research Report

On January 6, 2014, Envision Healthcare Holdings, Inc.'s (Envision Healthcare
Holdings) stock advanced by 4.07%, closing the day's trading session at
$35.29. In the past three-day trading period, the Company's shares decreased
0.65%, compared to the S&P 500 Index which fell 1.17% over the same trading
period. The Full Research Report on Envision Healthcare Holdings, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4b31_EVHC

Fonar Corp. Research Report

On January 6, 2014, Fonar Corp.'s (Fonar) stock advanced 20.19% to end the
day's trading at $23.99. Over the past three-day trading sessions, Fonar's
shares reflected an increase of 13.11%, compared to the Dow Jones Industrial
Average Index which declined 0.91% during the same three-day trading period.
The Full Research Report on Fonar Corp. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/73cc_FONR

Idera Pharmaceuticals, Inc. Research Report

On January 6, 2014, Idera Pharmaceuticals, Inc.'s (Idera Pharmaceuticals)
stock gained 1.00%, closing the day at $5.04. During the past three-day
trading period, Idera Pharmaceuticals' shares increased 8.86%, compared to the
Nasdaq Composite Index which fell 1.51% over the same three-day trading
session. The Full Research Report on Idera Pharmaceuticals, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/0b86_IDRA

Neurocrine Biosciences Inc. Research Report

On January 6, 2014, Neurocrine Biosciences Inc. (Neurocrine) announced
positive results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study. According to
the Company, a small molecule VMAT2 inhibitor, NBI-98854 showed a
statistically significant and clinically meaningful reduction in tardive
dyskinesia symptoms in the Phase IIb Kinect 2 study. Additionally, Neurocrine
stated that the pre-specified primary endpoint was the change-from-baseline in
the Abnormal Involuntary Movement Scale (AIMS) at Week 6 as assessed by
central blinded video raters. Commenting on the update, Christopher F.
O'Brien, Chief Medical Officer of Neurocrine, said, "The profound response in
this Kinect 2 study demonstrates the potential of NBI-98854 as both a safe and
highly effective treatment for patients suffering from tardive dyskinesia. It
is clear from these results that the use of blinded central AIMS raters
coupled with the ability to titrate up to 75 mg of NBI-98854 were both
critical to the success of this trial." The Full Research Report on Neurocrine
Biosciences Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8228_NBIX

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.